摘要
目的探讨肾癌中miR-122的表达特点及临床意义。方法基于前期平行测序的工作基础,对51例肾癌及相应癌旁组织、15例肾癌患者血清及15例健康对照者血清中miR-122的表达水平进行RT-qPCR检测,分析miR-122的表达高低与肾癌患者临床病理特征之间的相关性;并通过在肾癌细胞系(786-O和ACHN)中转染miR-122inhibitors,观察转染后细胞的增殖改变,初步探讨miR-122的生物学功能。结果相对于癌旁组织,肾癌组织中miR-122表达水平明显升高,上调率为82.35%;相比于健康对照者血清,肾癌患者血清中的miR-122表达亦明显升高,上调率为100%。肾癌组织中miR-122的表达水平与肾癌患者的临床病理特征无显著相关性(P>0.05)。在肾癌细胞系(786-O和ACHN)中转染miR-122inhibitors后,肿瘤细胞的增殖受到抑制。结论 miR-122可能参与到肾癌的病理过程,研究肾癌中miR-122的表达特点及生物学功能可能对早期诊断及治疗肾癌具有潜在的临床价值。
Objective To explore the expression levels of miR-122 in the tumor tissues and sera of patients with renal cell carcinoma and analyze its clinical significance.Methods Total RNAs from 51 pairs of human renal cell carcinoma and matched adjacent normal tissues were isolated and used for synthesis of the first-strand cDNA.Meanwhile,15 pairs of serum samples from cancer patients and matched healthy control subjects were subjected to RNA isolation and reverse transcription.The expression levels of miR-122 were analyzed by quantitative real-time PCR.Then,the relationship between the expression level of miR-122 in tumor tissue and clinicopathological characteristic was investigated.Furthermore,ACHN and 786-O cell lines were transfected with miR-122 inhibitors for characterization of the biological function of miR-122.Results Compared with the corresponding adjacent tissues and matched serum controls,the expression levels of miR-122 in tumor tissues and patients＇ sera were significantly increased,with calculated ratio of upregulation at 82.35 percent and 100 percent,separately.However,there＇s no correlation between the expression level of miR-122 and the age,gender,pathological classification and TNM stage of patients with renal cell carcinoma.MTT assay showed that tumor cells transfected with synthesized miR-122 inhibitors proliferated at a lower rate than that of control groups.Conclusion miR-122 may be involved in the development and progression of renal cell carcinoma.This study of miR-122 expression may display potential application significance for the early diagnosis and treatment of renal cell carcinoma.
出处
《中国实验诊断学》
2016年第4期559-563,共5页
Chinese Journal of Laboratory Diagnosis
基金
深圳市科技计划项目(JCYJ20140415162543037)
深圳市卫生计生系统科研项目(201401049)
